08:16 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

NuCana plc (NASDAQ:NCNA) reported interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an objective response rate (ORR) of 50% in eight evaluable patients with...
21:51 , Jan 19, 2018 |  BC Extra  |  Clinical News

NuCana gains on first-line biliary cancer readout

NuCana plc (NASDAQ:NCNA) jumped $6.02 (42%) to $20.51 on Friday after reporting interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an objective response rate...
21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

NuCana raises $100M IPO

On Sept. 27, cancer company NuCana plc (NASDAQ:NCNA) raised $100 million through the sale of 6.7 million ADSs at $15 in its IPO underwritten by Citigroup, Jefferies, Cowen and William Blair. Each ADS represents one...
22:37 , Sep 28, 2017 |  BC Extra  |  Financial News

Nightstar, Deciphera, NuCana price IPOs

Nightstar Therapeutics plc (NASDAQ:NITE), Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and NuCana plc (NASDAQ:NCNA) each priced IPOs after market hours Wednesday, raising more than $300 million. Ophthalmic gene therapy company Nightstar gained $10 (71%) to $24 in...
16:17 , Sep 8, 2017 |  BC Week In Review  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Aug. 31 in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush...
21:35 , Sep 1, 2017 |  BC Extra  |  Financial News

Nightstar, Deciphera, NuCana propose NASDAQ IPOs

Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to $86.3 million on Thursday in an IPO on NASDAQ underwritten by Jefferies, Leerink, BMO Capital Markets, Wedbush and...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Acelarin: Phase Ib data

Data from 20 evaluable patients with recurrent platinum-resistant ovarian cancer in the open-label, dose-escalation, U.K. Phase Ib ProGem2 trial showed that Acelarin given on days 1 and 8 every 21 days plus carboplatin led to...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Acelarin: Phase I/II final data

Final data from an open-label, U.K. Phase I/II trial in 49 evaluable patients with advanced solid tumors showed that IV Acelarin led to a disease control rate (DCR) of 78%, including 5 partial responses and...
07:00 , Apr 14, 2014 |  BioCentury  |  Finance

Double vision

Double vision Sofinnova Ventures led NuCana BioMed Ltd. 's $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market. NuCana's ProTide technology adds a phosphoramidate moiety...
00:26 , Apr 11, 2014 |  BC Extra  |  Financial News

NuCana raises $57 million in series B

NuCana BioMed Ltd. (Edinburgh, U.K.) raised $57 million in a series B round led by new investor Sofinnova Ventures. Existing investors Sofinnova Partners; Morningside Ventures; Alida Capital International; and the Scottish Investment Bank also participated....